Diabetes type 2 metabolic diseases
Conditions
Interventions
The food products will be consumed in fasting state as a breakfast. All control
products contain 50g available carbohydrates. In the drinks, one treatment 30%
(i.e. 15g) of the sucrose will be repla
in the cereal clusters
10% and 15% sucrose will be replaced by L-arabinose.
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • 18-35 Years old while signing the informed consent • Good Dutch speaking, writing, understanding • Healthy: as judged by the subject • Stable body weight, i.e. no reported weight loss or weight gain of > 5 kg in the two months prior to the screening session • Normal fasting glucose concentration 8.5 mmol/L for men and >7.5 mmol/L for females, measured by finger prick
Exclusion criteria
Exclusion criteria: • Women being pregnant or lactating • Allergy, intolerance or oversensitivity for food products • Having a history of medical or surgical events that may affect the study outcome • Having reported gastro-intestinal problems • Medical drug use that may affect the study outcome • Current antibiotics usage or in the two months prior to the screening session • Not willing to eat or drink the test products • Use of dietary supplements that may affect the study outcome • Currently using a slimming or medically prescribed diet or having used one in the two months prior to the screening session • Excessive alcohol consumption (>21 glasses/week on average) • Planning to change physical activity pattern during the study period • Having blood vessels that are too difficult for inserting a cannula, as judged by the study nurse • Recent blood donation (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Glycaemic response, measured as iAUC, peak and time-to-peak of blood glucose during 180 minutes; 2) Insulinemic response, measured as AUC, peak and time-to-peak of plasma insulin during 180 minutes; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3) L-arabinose in plasma; 4) GLP-1 in plasma; 5) Subsequent ad libitum food intake, measured as total energy and macronutrient intake; 6) Appetite feelings, measured by a VAS-questionnaire at multiple time points during 180 minutes; 7) Gastro-intestinal comfort using a questionnaire; 8) Study diary; 9) L-arabinose in urine. | — |
Countries
Netherlands
Outcome results
None listed